Category: Down Syndrome

Jovenes con Síndrome de Down mejoran su aprendizaje

NEWS JUNE 2016 ON FONTUP

NEW DATA AND NEWS ON JUNE 2016 FONTUP

I am back again to share with you some new data on FontUp.

As you know, this is a commercial product containing the right amount of epigallocatechin gallate (EGCG), a compound of green tea that, together with cognitive stimulation, enhances the capabilities in Down syndrome. Thus, I refer you to a post on my website about some historical data prior FontUp. The link is:

http://www.doctorlozano.com/down-syndrome-some-historical-data-prior-to-fontup/

Firstly, I would like to remind you that I do not have any commercial relationship with the company that manufactures FontUp. On the contrary, I only feel gratitude towards it due to a couple of reasons: being myself the father of a young woman with Down syndrome, and as a scholar of this field and especially of her mental health.

To give an overall picture of the post or go to the data that interest them as I bring my style, a brief table of contents or index:

1. Publication in the journal "The Lancet Neurology."

The results of phase 2 clinical trials were published on June 7, 2016, in the prestigious journal "The Lancet Neurology"."De la Torre et al. Safety and efficacy of cognitive training plus epigallocatechin-3 gallate for cognitive improvement in young adults with Down syndrome (TESDAD): a double-blind, randomised controlled, phase 2 trial. Lancet Neurology. 2016, 15: 801-810"

http://dx.doi.org/10.1016/S1474-4422(16)30034-5

http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(16)30034-5/abstract

It shows evidence that epigallocatechin gallate (EGCG), a compound present in green tea, along with a protocol of cognitive stimulation, can improve some intellectual abilities in young adults with Down syndrome.

2. Beginning of a study on EGCG in children aged between 1 and 15 years.

The research could be widened, and there is the aim to conduct the same survey with kids in paediatric ages

To see whether the effects obtained in adults are repeated in children. It exists the premise that neurodevelopmental processes in children are more plastic, and that the Dyrk1A gene and an excess of its Dyrk1a protein start acting and have a very active role in the development of children's nervous system.

3. FontUp in America.

I am informed that there is a delay in the distribution of the product

. The company that manufactures it is not responsible for it as it seems there are some problems with the patent of the name and that production has been overtaken by the sales in Spain. However, it will arrive within a short period to your country.

4. FontUp in Chile.

Chile is the first country in America to be distributed. Moreover, the date is very early: on August 25! And Dr Rafael La Torre will be in a chat together with ALLERGIKA, the distributor company. Those interested can join the contact list:

Chile is the first country in America to be distributed. Moreover, the date is very early: on August 25!

And Dr Rafael La Torre will be in a chat together with ALLERGIKA, the distributor company. Those interested can join the contact list:

http://www.allergikachile.com/producto/fontup/

5. FontUp's online availability in Spain:

I leave you some links to FontUp's online purchase, with which you can save some money when buying it:

I leave you some links to FontUp's online purchase, with which you can save some money when buying it:

http://www.farmaciamartorell.com/otros-productos/fontup.html

http://www.mifarma.es/laboratoires-grand-fontaine-fontup-down-6-un?fee=12&fep=35139&gclid=CNjivqbIpM0CFRUTGwod_ZQFwg

http://www.lafarmaciademodesta.com/nutricion-y-fitoterapia/nutricosmeticos/font-up-14-sobres-sin-gluten-sin-lactosa.html

Currently, Farmacia Soler is the one offering better terms: € 17.50 and with free shipping from € 60.

http://www.farmaciasoler.com/laboratorio-grand-fontaine-fontup-sabor-chocolate-14-sobres-p-18329.html#

6. I would like to remind you that FontUp does not cure Down syndrome

Although it is not a cure, there is a treatment showing some efficacy in this syndrome for the first time and opening the door to new research to treat a syndrome, which was believed to be an orphan

. I remind you Dr Dierssen's words, head of the group of Cellular Neurobiology and Systems at the Centre for Genomic Regulation and lead author of the study. "It is the first time a treatment proves effective in cognitive improvement of people with this syndrome. However, it must be clear that our discovery is not a cure for Down syndrome, but it can be a tool to improve the quality of life of these people."

7. The Lancet Neurology article commented in Spanish.

For those of you with some difficulties in reading the original article

, I refer you to this link of the Fundación Down21, which does an excellent job as usual.

http://www.down21.org/noticias/2944-lancet-neurology-te-verde-y-estimulacion-cognitiva-para-la-mejora-de-las-capacidades-en-sindrome-de-down.html

Uso FontUp en personas con síndrome de Down

Down syndrome: Some historical data prior to FONTUP

CONTENIDO

DOWN SYNDROME: SOME HISTORICAL DATA PRIOR TO FONTUP.. 2

Dr. Dierssen and Dr. de la Torre. 25 years researching. 2

In 1996, 19 years ago, in the fly Drosophila model Down syndrome. 2

In 2001, overexpression of the gene in the mouse Dyrk1A model Down Syndrome 2

In 2003 epigallocatechin-3-gallate (EGCG) is identified. 2

In 2009 the cerebral protective effect is confirmed. 3

In 2014, the pilot study with EGCG evidence cognitive enhancement 3

In 2015, FontUp is dispensed at pharmacies in Spain. 3

THERAPEUTIC BASIS OF THE FONTUP ACTION.. 3

Before using FontUp there is a brain damage caused by the overexpression of Dyrk1A, reflected in: 4

After the use of FontUp in people with Down syndrome: 4

MARA DIERSSEN1 SAYS: 4

ACCORDING TO RAFAEL DE LA TORRE1: 5

FREQUENTLY ASKED QUESTIONS.. 6

1. Is FontUp a medicine?. 6

2. What are its main characteristics?. 7

3. Will it help to cure Down syndrome?. 7

4. What about its indications?. 7

5. Medical advice13: 7

6. What is the correct dosage?. 7

7. How to use it 7

8. When is the effect noticed?. 8

9. What is EGCG (epigallocatechin gallate)?. 8

10. Does FontUp improve knowledge by itself?. 8

11. Does it change something in the brain?. 8

12. How are these changes manifested in people with Down syndrome?. 9

13. Who should take FontUp?. 9

14. Format 9

15. What are its ingredients?. 9

16. Is there a more recent study of the effectiveness of FontUp?. 9

LINK TO THE VIDEO: 10

BIBLIOGRAPHY.. 10

DOWN SYNDROME: SOME HISTORICAL DATA PRIOR TO FONTUP

Dr. Dierssen and Dr. de la Torre. 25 years researching

Scientists Mara Dierssen and Rafael de la Torre, outstanding scientists in the field of Down Syndrome have been working for 25 years (as Director and researcher of the Centre for Genomic Regulation in Barcelona and the Institute IMIM - Hospital del Mar Research, respectively) to share their studies’ results with people and in this case to arrive at a therapy that improves cognitive abilities of people with Down syndrome[1].

In 1996, 19 years ago, in the fly Drosophila model Down syndrome

In 1996, 19 years ago, the Drosophila model of Down syndrome was located, the overexpression of the MNB gene (homologous to Dyrk1A -Dual Dual specificity tyrosine-phosphorrylation-regulated kinase 1A) results in abnormal defective development[2]. 

In 2001, overexpression of the gene in the mouse Dyrk1A model Down Syndrome

In 2001, the Dyrk1A gene overexpression in Down syndrome model mouse is related to defects in brain volume and neuronal density[3].

In 2003 epigallocatechin-3-gallate (EGCG) is identified

In 2003, the Epigallocatechin -3- Gallate (EGCG) contained in the green tea extract as a potent inhibitor in vitro of Dyrk1A4 gene[4] is identified.

In 2009 the cerebral protective effect is confirmed

In 2009, the cerebral protective effect against overexpression Dyrk1A, through its inhibition by EGCG in vivo[5] is confirmed.

In 2014, the pilot study with EGCG evidence cognitive enhancement

In 2014, the pilot study with EGCG shows cognitive enhancement in mice and humans with Down syndrome[6].

In 2015, FontUp is dispensed at pharmacies in Spain.

 

THERAPEUTIC BASIS OF THE FONTUP ACTION

Trisomy 21 in people with Down syndrome involves Dyrk1A gene overexpression that generates excessive kinase activity which is detrimental to brain function. EGCG, the major flavonol green tea extract and bioactive component of the FontUp, proved an effective regulation of DYRK1A hyperactivity in people with Down syndrome[7].

Down Syndrome FontUp

Down Syndrome FontUp

Before using FontUp there is a brain damage caused by the overexpression of Dyrk1A, reflected in:

1.  Decreased brain volume.
2.      Reduced neuronal density in key regions.
3.      Decreased neuronal plasticity.

Enter your text here...

After the use of FontUp in people with Down syndrome:

Normalization of the enzymatic phosphorylation by the ability of the green tea (EGCG) to inhibit the kinase activity of Dyrk1A.

MARA DIERSSEN1 SAYS:

• The neurons receive information through the synapse.
• Cognition depends on the collective functioning of neurons.
• A process that depends on the plasticity of neurons which in intellectual disability are less able to adapt and connect to each other.
• We have searched to find key molecules in mental processes to improve cognitive abilities.
• Using mice with trisomy 21 enabled the finding of the Dyrk1a gene.
• This gene can enhance many important proteins for brain plasticity.
• By Overexpressing this gene impressive results are achieved, such as the growth of neurons.
• To do so, the expert said, they looked for a safe substance.
• That is Epigallocatechin Gallate (EGCG) found in green tea. In addition, this substance met an essential requirement: it is not toxic.
• In addition to treatment with EGCG for the study they used cognitive stimulation, a factor without which it is impossible to enhance the cognitive abilities of people with Down syndrome.
• The best chance is to do so in the first years of life, which is when the brain grows the most.
 

ACCORDING TO RAFAEL DE LA TORRE1:

 
• The absence of adverse effects with EGCG was one of the first and most important conclusions obtained in the investigation.
• However, when stopping the treatment the results of those involved in the investigation returned to the starting point.
•That is why cognitive stimulation is essential to maintain the effects of treatment over time.
• Exercises that stimulate their cognitive abilities. The investigation has included a specially designed website for this purpose, in which study participants could get exercises that stimulate their cognitive abilities, which were held from 2-3 hours per week. All this was monitored by experts.
• Green tea is not the solution per se.
• The appropriate cognitive stimulation adapted to age and technologies is predominant.
In addition, the EGCG may also help prevent the cognitive decline of aging, more present in people with Down syndrome, and Alzheimer's disease.
As for the age recommendation for use, it is currently 16 to 32 years.
Ø  Dierssen pointed out that in order to make a final recommendation to the families of children with Down syndrome up to the age of 12, when the treatment has the greatest effect; we will have to wait until the year 2020. 
Ø  Rafael de la Torre added that they could soon give an answer for the population of 12 to 80 years.
Down syndrome and FontUp

Down syndrome and FontUp

 

FREQUENTLY ASKED QUESTIONS

 

1. Is FontUp a medicine?

It is a dietary treatment whose bioavailability has been clinically tested7. It has been specially formulated to meet the nutritional needs of people with Down syndrome. It is a complete diet supplement with all necessary nutrients, 13 vitamins and 15 minerals.

1. It contributes to the control of postprandial8 glucose (the amount of blood sugar two hours after eating , which should not exceed 140 mg to avoid serious complications ) because they are high in soluble fiber (Nutriose®).

2. It helps regulate intestinal transit, preventing constipation, for the combination of its unique blend of soluble fibers (FOS y Nutriose®) 9.

3. It contains 100 % high biological value whey protein.

4.      It is suitable for people with celiac disease, as a nutritional solution without gluten10.
5.      Lipid profile balanced rich in linoleic acid, which helps reduce cholesterol 11. EGCG also helps decrease cholesterol levels.

6. EGCG making fasting avoidable, ensuring optimum bioavailability7.

7. Delicious chocolate flavor that ensures adherence12.

2. What are its main characteristics? (According to its data sheet15)

a. Powdered nutritional drink rich green tea extract (266mg / serving. Minimum 94 % EGCG). Rich in fiber (8g / serving), whey protein High bioavailability (8g / serving).

b. Gluten free.

c. Lactose free.

3. Will it help to cure Down syndrome?

It is not a cure for the syndrome, but for the first time there is safe and effective treatment for improving the cognitive performance of people with Down syndrome.

4. What about its indications? (According to its data sheet15)

Dietary treatment of cognitive performance deficits in people with Down syndrome - as a result of years of research on green tea extract (EGCG) in Down syndrome.

5. Medical advice13:

a. Use under medical supervision.

b. Do not administer to children under 16 years old.

c. Do not use in people with galactosemia.

d. No administered by gavage or parenterally.

e. Not for use as a sole source of nutrition.

f. Maximum recommended dose, two sachets a day.

6. What is the correct dosage? (According to its data sheet15)

a.      The dosage should be determined by a physician and depends on the weight and medical condition of 
the person
13.
b.    Divide the recommended daily dose into two doses: one half in the morning and the other half at night13.
c.       Do not take more than two sachets a day13.
 

7. How to use it (According to its data sheet15)

a. To prepare a beverage, add the contents of one to 100 ml of water.

b. Stir vigorously until completely dissolved.

8. When is the effect noticed?

a. After three months of dietary treatment with EGCG significantly improved episodic memory (Figure RESULTS De la Torre 2014) and learning is observed 1.

b. Moreover this improvement corresponds to a decrease in homocysteine ​​levels (equivalent to the activity of biomarker DYRK1A) 1.

9. What is EGCG (epigallocatechin gallate)?

a. It is one of many substances present in the green tea.

b. In green tea, naturally, a very small proportion of EGCG is present.

c. The amount necessary to achieve an appreciable effect is only obtained with a concentration of the molecule in suitable doses.

d. This is why regular consumption of green tea does not generate the necessary cognitive enhancement effect and a concentrated product of EGCG has been prepared to solve the problem.

e. Of course, excessive consumption of green tea is not recommended.

10. Does FontUp improve knowledge by itself?

a. The drink itself is beneficial for the cognitive development of people with Down syndrome; it is highly advisable to combine treatment with cognitive stimulation protocol.

b. Various institutions offer options of Down syndrome stimulation adapted to the age of the person.

It is ideal is to focus on the training of the:

1. Memory

2. Attention

3. Language skills

4. Executive functions

5. This stimulation should be applied regularly and systematically.

11. Does it change something in the brain?

Significant changes occur in areas of:

a. Memory

b. Executive functions:

1. The organization , establishing an order of priorities and entrepreneurship

2. The ability to focus and to create and shifting attention to tasks.

3. Regulating alertness, sustaining effort and processing speed.

4. The managing of frustration and modulating emotions.

5. The use of working memory and accessing memories.

6. The act of self- monitoring and self -regulation.

12. How are these changes manifested in people with Down syndrome?

a. In an overall improvement of autonomy and competence to function in daily life.

b. Increased learning ability in reading, writing and arithmetic.

c. Better social functioning.

d. Increase related to memory and self-control areas.

13. Who should take FontUp?

a) People with Down syndrome.

b) Age: between16 and 34 years old.

1. It's not that it is useless or that it is harmful outside this age range

2. Simply the study has been carried out in people those ages.

3. We have to await studies of people under 16 or older than 34 years, to be recommended.

14. Format (According to its data sheet15)

a. Case: 686 g, 14 sachets of 49 g

b. Shelf life: 18 months before opening.

c. Taste: Chocolate

15. What are its ingredients? (According to its data sheet15)

Maltodextrin

Whey proteins

Soluble fiber (resistant dextrin, fructooligosaccharides)

Vegetable oils (palm, palm kernel, canola, sunflower, high oleic sunflower)

Sugar

Cocoa powder

Mineral salts (sodium, potassium, chloride, calcium, phosphorus, magnesium,

iron, zinc, copper, manganese, iodine, selenium)

Green tea extracts 0.5%

Flavoring (vanilla)

Emulsifier (soy lecithin)

Vitamins (C, niacin, E, D, B6, B2, B1, A, folic acid, biotin, K, D, B12)

Sweetener: sucralose

Fish oil

Antioxidants (extract rich in tocopherols and ascorbyl palmitate)

16. Is there a more recent study of the effectiveness of FontUp?

For clinical application of the treatment of cognitive performance deficits in Down syndrome and cognitive stimulation with EGCG download here the Executive Summary TESDAD 2015 study: "Effect of the combination of epigallocatechin gallate (EGCG) and a standardized cognitive stimulation protocol on cognitive tasks and responsibilities to the daily lives of young adults with Down Syndrome”[8].

http://www.ordesa.es/fontactiv/pdf/Tesdad_resumen_ejecutivo.pdf

Finally, the testimony of a mother expecting the EGCG in search of a better life for her daughter, emphasizing excellence in the results is provided.

LINK TO THE VIDEO:

https://www.youtube.com/watch?v=othHR9tWjGk&feature=youtu.be

 

BIBLIOGRAPHY

1. Dierssen M. y Torre R.:Estudio sobre los efectos de un compuesto presente en el té verde, que puede contribuir en la mejora cognitiva de las personas con síndrome de Down” Discurso a la Asamblea General de DOWN ESPAÑA el 26 de abril del 2014.

2. Guimerá J, Casas C, Pucharcós C, Solans A, Doménech A, Planas AM, et at.A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region”. Hum Mol Genet. 1996; 5 (9):1305-10.

3. Altafaj X, Dierssen ñ, Baamonde C, Martí E, Visa J, Guimerá J, et al. Neurodevelopmental delay, motor abnormalities and cognitive déficits in transgenic mice overexpressing DyrklA (minibrain ), a murine model of Down ' s syndrome”. Hum Mol Genet. 2001; 10 (18):1915-24.

4. Bain J, Lauchlan HMC, Elliott M, Cohén P. The specificities of protein kinase inhibitors: an update. Biochem J. 2003; 204 (371):199-204.

5. Guedj F, Sébrié C, Rivals I, Ledru A., Paly E, Bizot JC, et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One. 2009 Jan; 4{2):e4606.

6. De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farré M, et at. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive déficits in Down syndrome mouse models and in humans. Mol Nutr Food Res. 2014 Feb; 58 (2):278-88.

7. De la Torre R. “Estudio farmacocinético y biodisponibilidad comparativa de la epigalocatequina galato ( EGCG ) de tres preparados de té verde en voluntarios sanos y voluntarios con síndrome de Down. Barcelona; 2014 p. 1-47.

8. C L-M. Nutrióse® a useful soluble dietary fibre for added nutritional valué. Nutr Bull. 2008; 33:234-9.

9. Lavin JLS, Avarino VS, laz APA. AReview of the Role of Soluble Fiber in Health with Specific Reference to Wheat Dextrin. J Int Med Res. 2009; 37:1-17.

10. Jennifer Dennis, Charlie Charlton GH. DOWN ' S SYNDROME COELIAC DISEASE / GLUTEN SENSITIVITY. 2000 p. 1-4.

11. Panel E, Nda A. Scientific Opinión on the substantiation of health claims related to linoteic acid and maintenance of normal blood cholesterol concentrations (ID 489} pursuant to Article 13 (1) of Regulation (EC) No 1924 / 2006 1. EFSA J. 2009; 7 (1924):1-12.

12. Jin J, Sklar GE, Min V, Oh S.Factors affecting therapeutic compliance: A review from the patient's perspective”. Ther Clin Risk Manag 2008; 4(1):269-86.

13. Literatura de FontUp que aporta el Laboratorio Grand Fontaine.

14. Resumen Ejecutivo del estudio TESDAD 2015: “Efecto de la combinación de la epigalocatequina galato (EGCG) y un protocolo estandarizado de estimulación cognitiva sobre funciones cognitivas y competencias en la vida diaria de adultos jóvenes con Síndrome de Downhttp://www.ordesa.es/fontactiv/pdf/Tesdad_resumen_ejecutivo.pdf

15. FontUp Data Sheet: http://www.ordesa.es/fontactiv/gama/fontup

16. Dierssen, M.: “Charla sobre el estudio del té verde” http://sindromedown.cat/es/2015/charla-coloquio-con-mara-dierssen-sobre-el-estudio-del-te-verde/



Llanto en la depresión
Depression or depressions?

Quick NavigationTHERE IS NO UNIQUE DEPRESSION.COMMON FEATURES of DEPRESSIVE DISORDERSTYPES OF DEPRESSIVE DISORDERSEven types …

Obsessive-compulsive disorders OCD
Obsessive-compulsive disorders (OCD – TOC)

For me, speaking about the obsessive disorder is to speak about an old enemy I must defeatI have faced it every day for over …

Jovenes con Síndrome de Down mejoran su aprendizaje
NEWS JUNE 2016 ON FONTUP

NEW DATA AND NEWS ON JUNE 2016 FONTUP I am back again to share with you some new data on FontUp. As you know, this is a commercial …